Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 17/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15340797 | 0.85 | MAPT (0.66) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL5054712 | 0.84 | MAPT (0.68) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL10061540 | 0.81 | MAPT (0.60) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL17919917 | 0.81 | MAPT (0.60) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL18036523 | 0.80 | MAPT (0.75) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2589998 | 0.79 | MAPT (0.69) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL2445796 | 0.79 | LMNA (0.75) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL4140342 | 0.77 | MAPT (0.67) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL10061539 | 0.77 | LGMN (0.59) | MAPTPKMALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL22652006 | 0.76 | MAPT (0.69) | MAPTPKMALDH1A1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | MAPT 4348/4885PKM 1535/4885ALDH1A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.